Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [4][6] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors involved in cough hypersensitivity [4] Industry Context - Refractory chronic cough (RCC) affects approximately 2-3 million patients in the U.S. and has no approved therapies, defined as a cough lasting over 8 weeks despite treatment for underlying conditions [3] - Chronic cough is prevalent in IPF patients, impacting up to 85% of this population, with around 140,000 IPF patients in the U.S. [5] - The condition can lead to significant social and economic burdens, including sleep disruption and social embarrassment [3] Upcoming Events - The company will hold a conference call and live webcast on March 10, 2025, at 8:30 a.m. ET to share topline results from the Phase 2a RIVER trial of Haduvio in patients with RCC [1][2]